Key result
Bioprosthetic MVR shows comparable 90-day readmission rates to mechanical MVR in infective endocarditis.
Why the study?
The association of prosthesis choice with readmission rates, causes of readmission, in-hospital mortality, cost, and length of stay in patients undergoing isolated mitral valve replacement for infectious endocarditis was evaluated.
Does bioprosthetic mitral valve replacement compared with mechanical mitral valve replacement affect readmission rates and in-hospital outcomes in patients with infective endocarditis?
Cohort (n=4,206)
Yes
Does bioprosthetic mitral valve replacement compared with mechanical mitral valve replacement affect readmission rates and in-hospital outcomes in patients with infective endocarditis?
Answers are grounded in this paper and cite their sources.
In patients undergoing isolated mitral valve replacement for infective endocarditis, prosthetic valve type (bioprosthetic vs mechanical) does not affect in-hospital mortality, length of stay, or 1-year readmission rates, indicating that valve choice should be guided by patient age and comorbidities rather than endocarditis status alone.
Objective In patients who underwent mitral valve replacement for infectious endocarditis, we evaluated the association of prosthesis choice with readmission rates and causes (the primary outcomes), as well as with in-hospital mortality, cost, and length of stay (the secondary outcomes). Methods Patients with infectious endocarditis who underwent isolated mitral valve replacement from January 2016 to December 2018 were identified in the United States Nationwide Readmissions Database and stratified by valve type. Propensity score matching was used to compare adjusted outcomes. Results A weighted total of 4206 patients with infectious endocarditis underwent bioprosthetic mitral valve replacement (n = 3132) and mechanical mitral valve replacement (n = 1074) during the study period. Patients in the bioprosthetic mitral valve replacement group were older than those in the mechanical mitral valve replacement group (median 57 vs 46 y, P < .001). After propensity matching, the bioprosthetic mitral valve replacement group (n = 1068) had similar in-hospital mortality, length of stay, and costs compared with the mechanical mitral valve replacement group (n = 1056). Overall, 90-day readmission rates were high (28.9%) and comparable for bioprosthetic mitral valve replacement (30.5%) and mechanical mitral valve replacement (27.5%, P = .4). Likewise, there was no difference in readmissions over a calendar year by prosthesis type. Readmissions for infection and bleeding were common for both bioprosthetic mitral valve replacement and mechanical mitral valve replacement groups. Conclusions Outcomes and readmission rates were similar for mechanical mitral valve replacement and bioprosthetic mitral valve replacement in infectious endocarditis, suggesting that valve choice should not be determined by endocarditis status. Additionally, strategies to mitigate readmission for infection and bleeding are needed for both groups.
No takes yet. Share an insight, caveat, or question.
Hogan et al. (2023) conducted a cohort in Infective endocarditis requiring isolated mitral valve replacement (n=4,206). Bioprosthetic mitral valve replacement (B-MVR) vs. Mechanical mitral valve replacement (M-MVR) was evaluated on 90-day readmission rate in propensity-matched cohort (p=0.39). Bioprosthetic versus mechanical mitral valve replacement in infective endocarditis resulted in comparable 90-day readmission rates in propensity-matched patients.
Synapse has enriched 10 related papers. Consider them for comparative context: